RBMX2 Antibody

What is RBMX2 and what are its primary biological functions?

RBMX2 (RNA binding motif protein X-linked 2) is a nuclear RNA-binding protein primarily involved in pre-mRNA splicing as a component of the activated spliceosome. More specifically, it functions as part of the minor spliceosome where it contributes to the splicing of U12-type introns in pre-mRNAs . Immunofluorescence analyses have consistently shown that RBMX2 is primarily localized to the nucleus in various cell lines including MCF7 and U-2 OS tumor cell lines . The protein appears to play critical roles in several fundamental biological processes, particularly in meiosis where it prevents selection of aberrant splice sites and the insertion of cryptic and premature terminal exons . Recent research has demonstrated that deletion of the retrogene encoding RBMX2, which is expressed in male germ cells of all placental mammals, blocks spermatogenesis, indicating its essential role in reproductive biology .

What applications are RBMX2 antibodies validated for in experimental research?

RBMX2 antibodies have been validated for multiple experimental applications, with varying recommended dilutions depending on the specific application and antibody format. Based on available research tools, RBMX2 antibodies are suitable for:

For Western blot applications, RBMX2 antibodies typically detect a band at approximately 37 kDa (predicted size) , though some researchers have observed bands at 30-31 kDa . When conducting immunofluorescence studies, paraformaldehyde (4-10%) fixed cells have shown good results with appropriate secondary antibodies .

What species reactivity has been confirmed for available RBMX2 antibodies?

Available RBMX2 antibodies demonstrate cross-reactivity with multiple species, though the extent of validation varies by antibody format and manufacturer. The primary confirmed species reactivity includes:

It's important to note that species reactivity is often based on sequence homology predictions, and researchers should verify antibody performance in their specific experimental systems . When working with novel model organisms, preliminary validation experiments are strongly recommended before proceeding with extensive studies.

How can researchers optimize RBMX2 antibody use in cancer research applications?

RBMX2 has shown significant relevance in cancer biology, with aberrant expression levels reported across multiple cancer types. When investigating RBMX2 in cancer contexts, researchers should consider these methodological approaches:

For expression analysis across cancer types:

• Use immunohistochemistry with optimized antibody dilutions (typically starting at 1:100) on tissue microarrays containing multiple cancer types alongside matched normal tissues.

• Employ paired sample analysis whenever possible, comparing tumor tissue with adjacent normal tissue from the same patient to control for individual variation .

• Quantify expression using established scoring systems that account for both staining intensity and percentage of positive cells.

For functional studies:

• Employ siRNA or shRNA knockdown approaches to investigate the consequences of RBMX2 depletion on cancer cell proliferation, migration, and invasion capabilities .

• Validate knockdown efficiency using both protein-level (Western blot) and mRNA-level (qPCR) assessments.

• Consider the relationship between RBMX2 and immune infiltration when designing experiments, as research has shown significant associations between RBMX2 expression and various immune cell populations .

Research has demonstrated that knockdown of RBMX2 can impair proliferation, migration, and invasion of liver cancer cells, suggesting its potential as a therapeutic target . When studying RBMX2 in hepatocellular carcinoma specifically, consider analyzing both the protein expression and splicing activity alterations.

What protocols are most effective for studying RBMX2 in the context of splicing mechanisms?

Given RBMX2's established role in pre-mRNA splicing, particularly in the context of U12-type introns, researchers investigating its splicing functions should consider these methodological approaches:

• RNA-sequencing analysis comparing transcriptomes between control and RBMX2-depleted cells, focusing on:

  • Differential exon usage analysis

  • Intron retention events

  • Cryptic splice site activation

  • Premature terminal exon inclusion

• RNA-immunoprecipitation (RIP) protocols:

  • Use validated RBMX2 antibodies at 5-10 μg per immunoprecipitation

  • Include appropriate negative controls (IgG or non-related antibody)

  • Perform stringent washing steps to minimize non-specific binding

  • Validate interactions using qPCR for predicted target RNAs

• Minigene splicing assays to directly assess RBMX2's impact on specific splicing events:

  • Design constructs containing exons of interest with their flanking intronic sequences

  • Transfect into cells with and without RBMX2 expression/depletion

  • Analyze splicing patterns using RT-PCR with primers targeting vector sequences

When analyzing differential gene expression between low- and high-RBMX2 subgroups in cancer samples, researchers can follow the methodology used in recent studies where the top 30% and bottom 30% of samples (based on RBMX2 expression) were compared using the "limma" R package, with adjusted p-values < 0.05 defining differential expression .

What are the optimal troubleshooting approaches for non-specific binding issues with RBMX2 antibodies?

When encountering non-specific binding with RBMX2 antibodies, consider these systematic troubleshooting approaches:

For Western blot applications:

• Optimize blocking conditions - test different blocking agents:

  • 5% non-fat dry milk in TBST has been successfully used in validated protocols

  • Consider alternative blockers such as 5% BSA if background remains high

• Titrate antibody concentration:

  • For monoclonal antibodies, test ranges from 1:1000 to 1:10000

  • For polyclonal antibodies, begin with higher concentrations (1:500) and increase dilution as needed

• Increase stringency of washing:

  • Extend washing times with TBST

  • Consider adding low concentrations of SDS (0.1%) to washing buffer

• Validate specificity using:

  • RBMX2 knockout/knockdown samples as negative controls

  • Peptide competition assays to confirm binding specificity

For immunofluorescence applications:

• Optimize fixation conditions:

  • 4% paraformaldehyde has been successfully used in published protocols

  • Consider comparing with methanol fixation if nuclear antigens are inadequately preserved

• Adjust permeabilization parameters:

  • Test different detergents (Triton X-100, Tween-20) at varying concentrations

  • Optimize incubation times for permeabilization step

• Reduce autofluorescence:

  • Include quenching steps (e.g., sodium borohydride treatment)

  • Use Sudan Black B to reduce lipofuscin-related autofluorescence in tissue sections

How can researchers determine the relationship between RBMX2 expression and immune cell infiltration in tumor microenvironments?

Recent research has highlighted RBMX2's potential associations with immune cell infiltration, suggesting its relevance in cancer immunity. To investigate these relationships:

• Employ multiplexed immunofluorescence approaches:

  • Use validated RBMX2 antibody alongside markers for specific immune cell populations

  • Include DAPI for nuclear counterstaining

  • Analyze co-localization and spatial relationships between RBMX2-expressing cells and immune cells

• Utilize computational approaches with public datasets:

  • Query databases like TIMER2 (http://timer.cistrome.org/) to assess correlations between RBMX2 expression and 21 immune cell subsets

  • Apply Spearman correlation analysis as demonstrated in published protocols

  • Visualize results using heatmaps to identify significant associations

• Validate computational findings with tissue samples:

  • Perform immunofluorescent staining to examine relationships between RBMX2 expression and myeloid-derived suppressor cells in clinical samples

  • Quantify colocalization using appropriate image analysis software

  • Compare results across different tumor types to identify cancer-specific patterns

Research has demonstrated that RBMX2 expression correlates with various immune cell populations including CD4+ T cells, regulatory T cells, NK cells, and macrophages, suggesting its potential role in modulating the tumor immune microenvironment .

What experimental approaches are most effective for studying RBMX2's role in meiosis and spermatogenesis?

RBMX2 has been identified as an ancient germ cell-specific RNA-binding protein critical for male fertility. To investigate its functions in reproductive biology:

• For animal model studies:

  • Generate tissue-specific conditional knockout models to bypass potential embryonic lethality

  • Employ Cre-recombinase systems under the control of germ cell-specific promoters

  • Analyze fertility, sperm parameters, and testicular histology in knockout versus control animals

  • Examine meiotic progression through chromosome spreading techniques

• For splicing analysis in germ cells:

  • Isolate stage-specific germ cells using techniques such as STA-PUT or FACS

  • Perform RNA-seq to identify transcriptome-wide splicing alterations

  • Focus on cryptic exon inclusion and aberrant terminal exon usage, which are particularly affected by RBMX2 deletion

• For protein interaction studies:

  • Conduct co-immunoprecipitation experiments using RBMX2 antibodies

  • Identify interaction partners through mass spectrometry

  • Validate interactions with known splicing factors

  • Map interaction domains through truncation mutants

Research has shown that RBMX2 deletion blocks spermatogenesis by disrupting splicing control during meiosis, particularly by failing to repress the selection of aberrant splice sites and insertion of cryptic exons . When designing experiments, consider that this mechanism may function by buffering high ambient concentrations of splicing activators to prevent disruption of gene expression.

How can researchers accurately assess and interpret RBMX2 expression patterns across different tissue types?

RBMX2 expression varies significantly across tissues, with particularly high expression in reproductive tissues. To accurately characterize these patterns:

• For multi-tissue expression analysis:

  • Employ tissue microarrays with antibody dilutions optimized for each tissue type

  • Include positive controls (tissues known to express RBMX2) and negative controls

  • Quantify nuclear staining intensity using digital pathology approaches

• For cell type-specific expression:

  • Use single-cell RNA sequencing to identify cell populations expressing RBMX2

  • Validate findings with multiplexed immunofluorescence combining RBMX2 antibodies with cell-type markers

  • Consider the subcellular localization patterns, as RBMX2 has been observed primarily in the nucleus of various cell types

• For developmental studies:

  • Analyze expression at different developmental stages, particularly during gametogenesis

  • Compare expression patterns between embryonic and adult tissues

  • Correlate expression with developmental milestones in specific tissues

When interpreting results, consider that RBMX2's primary function appears to be tissue-specific, with particularly important roles in male germ cells where it controls splicing patterns during meiosis . Understanding this context is crucial for accurate interpretation of expression data.

How can RBMX2 antibodies be utilized to investigate its potential as a cancer biomarker and therapeutic target?

Recent research has highlighted RBMX2's aberrant expression in multiple cancer types and its potential as both a biomarker and therapeutic target:

• For biomarker development:

  • Establish standardized immunohistochemistry protocols with optimized antibody concentrations

  • Develop scoring systems that account for both intensity and distribution of staining

  • Correlate expression with clinical outcomes using Kaplan-Meier survival analysis and Cox proportional hazards regression

  • Validate findings across independent patient cohorts

• For therapeutic targeting approaches:

  • Employ knockdown studies (siRNA/shRNA) to assess the impact on cancer cell phenotypes

  • Investigate combination approaches with standard therapies

  • Explore relationships with immune checkpoint molecules to identify potential synergies with immunotherapy

  • Develop assays to monitor splicing alterations as pharmacodynamic markers

• For patient stratification in clinical trials:

  • Establish RBMX2 expression thresholds that correlate with treatment response

  • Develop companion diagnostic approaches using validated antibodies

  • Incorporate RBMX2 testing into inclusion criteria for trials targeting splicing mechanisms

Research has demonstrated RBMX2's potential in predicting immunotherapy response, with significant differences in response rates between low and high RBMX2 expression groups across multiple cancer types . These findings suggest that RBMX2 testing could help identify patients most likely to benefit from immune checkpoint inhibitors.

What methodological approaches can detect alterations in RBMX2 protein-protein interactions under different cellular conditions?

Understanding how RBMX2's protein interaction network changes under different conditions is crucial for elucidating its functional roles:

• For mapping the complete interaction network:

  • Perform proximity-based labeling (BioID or APEX) with RBMX2 as the bait protein

  • Conduct tandem affinity purification followed by mass spectrometry

  • Validate key interactions using co-immunoprecipitation with RBMX2 antibodies

  • Create protein-protein interaction networks using computational tools and databases

• For studying condition-specific interactions:

  • Compare interaction profiles between normal and stressed conditions (e.g., DNA damage, hypoxia)

  • Analyze interaction changes during different cell cycle phases, particularly during meiosis

  • Examine how post-translational modifications affect RBMX2's interaction landscape

• For visualizing interactions in situ:

  • Employ proximity ligation assays (PLA) with RBMX2 antibodies and antibodies against suspected interaction partners

  • Use live-cell imaging with fluorescently tagged proteins to monitor dynamic interactions

  • Implement FRET-based approaches to confirm direct interactions

Protein-protein interaction analysis has revealed that RBMX2 interacts with proteins localized in multiple cellular compartments, including the mitochondria, nucleus, cytosol, secretory pathway, extracellular space, and membrane . Understanding these interaction networks is essential for developing targeted approaches to modulate RBMX2 function in disease contexts.

What are the emerging research questions regarding RBMX2 that remain to be addressed?

Despite significant advances in understanding RBMX2 biology, several critical questions remain:

• Mechanistic understanding:

  • How does RBMX2 specifically recognize its RNA targets?

  • What determines the specificity of RBMX2's interaction with U12-type introns?

  • How is RBMX2 expression and activity regulated during different cellular processes?

• Disease relevance beyond cancer:

  • Does RBMX2 play roles in neurodegenerative disorders, given the importance of splicing in neuronal function?

  • Are there genetic variants of RBMX2 associated with human disease, particularly male infertility?

  • How does RBMX2 function change during aging and cellular senescence?

• Therapeutic potential:

  • Can RBMX2 be specifically targeted without disrupting essential cellular functions?

  • Would modulating RBMX2 affect response to existing therapies, particularly in cancer?

  • Could RBMX2-targeting approaches be developed for male contraception, given its essential role in spermatogenesis?